scholarly journals Outpatient parenteral antibiotic therapy (OPAT) in Asia: missing an opportunity

2017 ◽  
pp. dkw551
Author(s):  
Dale Fisher ◽  
Jessica Michaels ◽  
Ryota Hase ◽  
Jing Zhang ◽  
Sushila Kataria ◽  
...  
Keyword(s):  
Antibiotic Therapy ◽  
Parenteral Antibiotic ◽  
Outpatient Parenteral Antibiotic Therapy

scholarly journals First Pediatric Outpatient Parenteral Antibiotic Therapy Clinic in Indonesia

2020 ◽  
Vol 8 ◽  
Author(s):  
Aryono Hendarto ◽  
Nina Dwi Putri ◽  
Dita Rizkya Yunita ◽  
Mariam Efendi ◽  
Ari Prayitno ◽  
...  
Keyword(s):  
Antibiotic Therapy ◽  
Parenteral Antibiotic ◽  
Outpatient Parenteral Antibiotic Therapy ◽  
Therapy Clinic

scholarly journals Risk Factors for Adverse Events in Children Receiving Outpatient Parenteral Antibiotic Therapy

2021 ◽  
Vol 11 (2) ◽  
pp. 153-159
Author(s):  
Elizabeth Townsley ◽  
Jessica Gillon ◽  
Natalia Jimenez-Truque ◽  
Sophie Katz ◽  
Kathryn Garguilo ◽  
...  
Keyword(s):  
Risk Factors ◽  
Adverse Events ◽  
Antibiotic Therapy ◽  
Parenteral Antibiotic ◽  
Outpatient Parenteral Antibiotic Therapy

Survival Times and Complications of Catheters Used for Outpatient Parenteral Antibiotic Therapy in Children

2007 ◽  
Vol 46 (3) ◽  
pp. 247-251 ◽  
Author(s):  
Sabiha Hussain ◽  
Margarita M. Gomez ◽  
Peter Wludyka ◽  
Thomas Chiu ◽  
Mobeen H. Rathore
Keyword(s):  
Antibiotic Therapy ◽  
Survival Times ◽  
Parenteral Antibiotic ◽  
Outpatient Parenteral Antibiotic Therapy

Rethinking Home-based Outpatient Parenteral Antibiotic Therapy for Persons Who Inject Drugs

2021 ◽  
Vol Publish Ahead of Print ◽  
Author(s):  
Raagini Jawa ◽  
Hallie Rozansky ◽  
Dylan Clemens ◽  
Maura Fagan ◽  
Alexander Y. Walley
Keyword(s):  
Antibiotic Therapy ◽  
Persons Who Inject Drugs ◽  
Parenteral Antibiotic ◽  
Outpatient Parenteral Antibiotic Therapy ◽  
Home Based

scholarly journals Is Once-Daily High-Dose Ceftriaxone plus Ampicillin an Alternative for Enterococcus faecalis Infective Endocarditis in Outpatient Parenteral Antibiotic Therapy Programs?

2020 ◽  
Vol 65 (1) ◽  
pp. e02099-20
Author(s):  
Laura Herrera-Hidalgo ◽  
Arístides de Alarcón ◽  
Luis Eduardo López-Cortes ◽  
Rafael Luque-Márquez ◽  
Luis Fernando López-Cortes ◽  
...  
Keyword(s):  
Single Dose ◽  
Infective Endocarditis ◽  
Antibiotic Therapy ◽  
Enterococcus Faecalis ◽  
High Dose ◽  
Synergistic Activity ◽  
Parenteral Antibiotic ◽  
Once Daily ◽  
Content Type ◽  
Outpatient Parenteral Antibiotic Therapy

ABSTRACTCeftriaxone administered as once-daily high-dose short infusion combined with ampicillin has been proposed for the treatment of Enterococcus faecalis infective endocarditis in outpatient parenteral antibiotic therapy programs (OPAT). This combination requires synergistic activity, but the attainment of ceftriaxone synergic concentration (Cs) with the regimen proposed for OPAT has not been studied. This phase II pharmacokinetic study enrolled healthy adult volunteers who underwent two sequential treatment phases. During phase A, volunteers received 2 g of ceftriaxone each 12 h during 24 h followed by a 7-day wash-out. Then the participants received phase B, which consisted of a single dose of 4 g of ceftriaxone. Throughout both phases, each volunteer underwent intensive pharmacokinetic (PK) sampling over 24 h. Ceftriaxone total and unbound concentrations were measured. Twelve participants were enrolled and completed both phases. Mean ceftriaxone total and free concentrations 24 h after the administration of 2 g each 12 h were 86.44 ± 25.90 mg/liter and 3.59 ± 1.35 mg/liter, respectively, and after the 4-g single dose were 34.60 ± 11.16 mg/liter and 1.40 ± 0.62 mg/liter, respectively. Only 3 (25%) patients in phase A maintained unbound plasma concentrations superior to the suggested Cs = 5 mg/liter during 24 h, and none (0%) in phase B. No grade 3 to 4 adverse events or laboratory abnormalities were observed. Ceftriaxone optimal exposure combined with ampicillin to achieve maximal synergistic activity against E. faecalis required for the treatment of infective endocarditis remains unknown. However, the administration of a single daily dose of 4 g of ceftriaxone implies a reduction in the time of exposure to the proposed Cs. (This study has been registered in the European Union Drug Regulating Authorities Clinical Trials [EudraCT] database under identifier 2017-003127-29.)

scholarly journals Dalbavancin Use in Vulnerable Patients Receiving Outpatient Parenteral Antibiotic Therapy for Invasive Gram-Positive Infections

2019 ◽  
Vol 8 (2) ◽  
pp. 171-184 ◽  
Author(s):  
Jacqueline T. Bork ◽  
Emily L. Heil ◽  
Shanna Berry ◽  
Eurides Lopes ◽  
Rohini Davé ◽  
...  
Keyword(s):  
Antibiotic Therapy ◽  
Gram Positive ◽  
Parenteral Antibiotic ◽  
Outpatient Parenteral Antibiotic Therapy ◽  
Vulnerable Patients
Sign in / Sign up

Export Citation Format

Share Document